Ivan Bergstein
Chief Executive Officer at STEMLINE THERAPEUTICS, INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kenneth Hoberman | M | 59 |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 11 years |
David Gionco | M | 63 | 10 years | |
Mark Sard | M | 59 |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 5 years |
Daniel Hume | M | 57 |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 5 years |
Jeffrey Levitt | M | - | 6 years | |
Matt Hoberman | M | - |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 2 years |
Nassir Habboubi | M | - | 3 years | |
Peter McDonald | M | - |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Shay Shemesh | M | 41 | 5 years | |
J. Buchi | M | 69 | 4 years | |
Eric Dobmeier | M | 55 | 6 years | |
Stephen Hall | M | 73 | - | |
Kenneth Zuerblis | M | 64 | 8 years | |
Christopher L. Brooks | M | - | - | |
Robert Francomano | M | 58 | 5 years | |
Jonathan Schwartz | M | 60 | 2 years | |
Enrique Poradosu | M | 58 | 4 years | |
Darren Cline | M | 59 | - | |
Mark Jacobson | M | 40 | 5 years | |
John Cavan | M | 65 | 6 years | |
Ronald Bentsur | M | 58 | 11 years | |
Thomas P. Cirrito | M | 51 | - | |
Alan Forman | M | 58 | 5 years | |
Eric Rowinsky | M | 67 | 5 years | |
Trishna Goswami | M | 46 | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 25 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ivan Bergstein
- Personal Network